Document is current
Any future updates will be listed below
-
Authors
Dourte, Marion
Paître, Esther
Bouchoucha, Mongia
Boyer, Emilien
Tomé, Sandra O.
Doeraene, Emilie
Huart, Caroline
Leroy, Karelle
Thal, Dietmar Rudolf
Decottignies, Anabelle
Hanseeuw, Bernard
Suelves, Nuria
Kienlen-Campard, Pascal
-
Funding
Funding for this research was provided by:
UCLouvain Action de Recherche Concertée
Fonds Wetenschappelijk Onderzoek Vlaanderen (1225725N)
Fonds Wetenschappelijk Onderzoek Vlaanderen (G065721N)
Fondation Louvain
SAO-FRA Alzheimer Research Foundation (SAO-FRA 2018/0025)
Queen Elisabeth Medical Foundation (FMRE AlzHEX)
F.R.S.-FNRS (FNRS J.0106.22)
- License Information
-
More Information
Article History
Received: 5 March 2025
Revised: 26 May 2025
Accepted: 27 May 2025
First Online: 19 June 2025
Declarations
:
: DRT and SOT received consultant honoraria from Muna Therapeutics. DRT collaborated with Novartis Pharma AG (Switzerland), and GE Healthcare (UK). The other authors have no competing interests to declare that are relevant to the content of this article.
: All animal procedures were conducted in accordance with institutional and European guidelines and approved by the UCLouvain Ethical Committee for Animal Welfare (2021/UCL/MD/018). Human postmortem brain tissue was collected in accordance with the applicable legislation in Belgium. The recruitment protocols for the collection of human brains were approved by the ethical committee (2020/02JUL/355).
